pulmonary fibrosis

News

Syndax shares fall as lung fibrosis drug fails trial

Syndax shares lost 17% of their value pre-market after the company said it abandoned development of axatilimab for idiopathic pulmonary fibrosis.

News

BMS eyes filings for idiopathic pulmonary fibrosis drug

Bristol Myers Squibb has reported phase 3 results with a new drug for idiopathic pulmonary fibrosis that could open the door to regulatory filings.

News

Brainomix AI lends weight to Endeavor Bio's IPF trial data

An AI-based imaging tool from Brainomix has been used to enrich data from a phase 2a trial of Endeavor's idiopathic pulmonary fibrosis drug taladegib.

News

UK first in Europe to clear Boehringer's IPF drug Jascayd

Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.

News

e-Lung software in the clinical setting, by Brainomix

Boehringer, Brainomix plan new trial of lung fibrosis AI

Boehringer and Brainomix are planning a prospective trial of an AI to diagnose pulmonary fibrosis, after positive results in an observational study.

News